Pulmatrix Inc (PULM) USD0.0001
Pulmatrix, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing inhaled therapies to address serious respiratory disease. The Company designs and develops inhaled therapeutic products based on its dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The Company's therapeutic candidates includes Pulmazole, for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma and in patients with cystic fibrosis (CF), PUR1800, for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) and PUR3100, for the treatment of acute migraine. The Company's each of this program is enabled by its iSPERSE formulation, designed to achieve specific therapeutic objectives.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.